Pharmacogenomics-Tailor made Drug Approach
Pharmacogenomics may permit drugs to be tailor-made for individuals and adapted to each person #39;s own genetic makeup. By,understanding an individual #39;s genetic...
By: Sukhnandan Kaur
Original post:
Pharmacogenomics-Tailor made Drug Approach - Video
HGP10: Translating Pharmacogenomics to Practice (Q A Session)
May 6, 2013 - Human Genome Project (HGP) 10th Anniversary Seminar Series More: http://www.genome.gov/27552250.
By: GenomeTV
Read more:
HGP10: Translating Pharmacogenomics to Practice (Q
Clinical Implications of Clopidogrel Pharmacogenomics - Pre-lecture video
Following this pre-lecture video, you should be able to understand how genetic and environmental factors play a role in clopidogrel efficacy, who should receive 2C19 genetic testing, and what therapeutic options are available in patients with a *2 CYP 2C19 allele.
By: Sean Kane
Read more:
Clinical Implications of Clopidogrel Pharmacogenomics - Pre-lecture video - Video
Dr. Matt McCarty from Genotox Labs: "Pharmacogenomics"
The misuse of prescription pills is an increasing concern in our society, but the entire pharmaceutical industry is evolving to help prevent addiction and ov...
By: kxan
More:
Dr. Matt McCarty from Genotox Labs: "Pharmacogenomics" - Video
Pharmacogenomics at Mayo Clinic
The right drug, at the right dose, for the right patient. Mayo Clinic uses the latest technologies to understand how drugs will work in individual patients, ...
By: Mayo Clinic
Continue reading here:
Pharmacogenomics at Mayo Clinic - Video
Pharmacogenomics: Regulatory aspects in Greece and the EU.
Pharmacogenomics: Regulatory aspects in Greece and the EU. In: 7th Golden Helix Pharmacogenomics Day, University of Patras, Conference and Convention Centre, Saturday, 20 October 2012 B iota; omicron; epsilon; pi; iota; sigma; tau; #942; mu; epsilon; sigmaf;, mu; omicron; chi; lambda; #972; sigmaf; alpha; nu; #940; pi; tau; upsilon; xi; eta; sigmaf; tau; eta; sigmaf; Kappa; omicron; iota; nu; omega; nu; #943; alpha; sigmaf;, Sigma; upsilon; nu; epsilon; delta; rho; iota; alpha; kappa; #972; kappa; alpha; iota; Pi; omicron; lambda; iota; tau; iota; sigma; tau; iota; kappa; #972; Kappa; #941; nu; tau; rho; omicron; tau; omicron; upsilon; Pi; alpha; nu; epsilon; pi; iota; sigma; tau; eta; mu; #943; omicron; upsilon; Pi; alpha; tau; rho; #974; nu;, Pi; #940; tau; rho; alpha;, 18 -- 20 Omicron; kappa; tau; omega; beta; rho; #943; omicron; upsilon; 2012
By: Chi; alpha; rho; #940; lambda; alpha; mu; pi; omicron; sigmaf; Kappa; alpha; tau; sigma; omicron; #973; lambda; alpha; sigmaf;
See the rest here:
Pharmacogenomics: Regulatory aspects in Greece and the EU. - Video
OMICS Group - Journal of Pharmacogenomics and Pharmacoproteomics-2153-0645-3-112
OMICS Group is an Open Access publication model that enables the dissemination of research articles to the global community. Thus, all articles published under Open Access can be accessed by anyone.
By: OMICSGroup I Articles
View post:
OMICS Group - Journal of Pharmacogenomics and Pharmacoproteomics-2153-0645-3-112 - Video
Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic...
... evaluation of medicinal products Session 1: Pharmacogenomics: regulatory and methodological implications in early clinical development Speaker: Marc Maliepaard, CHMP-Pharmacogenomics Working Party member Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1 0ratingsTime:29:13More inScience Technology
View post:
Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic... - Video
Session 6: Genomics in Patients with Japanese ancestry
Session 6: Pharmacogenomics in the global landscape: Pharmacogenetics and Ethnicity Speaker: Yoshiaki Uyama, PMDA, Regulatory Science, Japan Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1 0ratingsTime:26:16More inScience Technology
Read more:
Session 6: Genomics in Patients with Japanese ancestry - Video
Pharmacogenomics Sarah and Najma
Sorry for the quality!
By: piglet7th
Go here to see the original:
Pharmacogenomics Sarah and Najma - Video
Session 2: Panel discussion (Q A and Discussion)
Session 2: Methodology and adaptive designs and in confirmatory clinical trials Discussants: Emmanuel Zuber, Mathias Chiano, Marie Watissee Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:2 0ratingsTime:26:39More inScience Technology
Original post:
Session 2: Panel discussion (Q
Session 6: Genomics in Patients with Hispanic ancestry
Session 6: Pharmacogenomics in the global landscape: Pharmacogenetics and Ethnicity Speaker: Adrian Llerena, CHMP-Pharmacogenomics Working Party member Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:26:36More inScience Technology
Follow this link:
Session 6: Genomics in Patients with Hispanic ancestry - Video
Session 1: Panel discussion
Session 1: Pharmacogenomics: regulatory and methodological implications in early clinical development Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1 0ratingsTime:18:55More inScience Technology
Original post:
Session 1: Panel discussion - Video
Session 4: Pharmacogenomics guided treatments in clinical care: experience from...
...patients and health care professionals (HCPs) Speaker: David Haerry, EATG, Belgium Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:7 0ratingsTime:14:30More inScience Technology
View post:
Session 4: Pharmacogenomics guided treatments in clinical care: experience from... - Video
Session 4: Pharmacogenomics: a long(er) learning curve? Opening keynote lecture
Session 4: Pharmacogenomics guided treatments in clinical care: experience from patients and health care professionals (HCPs) Speaker: Hans Georg-Eichler, Senior Medical Officer, EMA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:4 0ratingsTime:19:01More inScience Technology
Read more from the original source:
Session 4: Pharmacogenomics: a long(er) learning curve? Opening keynote lecture - Video
Opening keynote lecture
Genomics in science and clinical care Speaker: Frédérique Nowak, French National Cancer Institute (INCa), France Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:42:44More inScience Technology
Here is the original post:
Opening keynote lecture - Video
Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor...
...as a Therapy for Cystic Fibrosis Session 1: Pharmacogenomics: regulatory and methodological implications in early clinical development Speaker: Federico Goodsaid, Vertex Pharmaceuticals, USA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1 0ratingsTime:32:26More inScience Technology
See the original post:
Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor... - Video
Session 6: Closing remarks
Session 6: Pharmacogenomics in the global landscape: Pharmacogenetics and Ethnicity Speaker: Tomas Salmonson, Chairman of the Committee for Medicinal Products for Human Use, EMA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:04:42More inScience Technology
Here is the original post:
Session 6: Closing remarks - Video
Session 4: Panel discussion
Session 4: Pharmacogenomics guided treatments in clinical care: experience from patients and health care professionals (HCPs) Panel discussion Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:37:55More inScience Technology
Session 4: Clinical implementation: a 7 year experience
Session 4: Pharmacogenomics guided treatments in clinical care: experience from patients and health care professionals (HCPs) Speaker: Ronald van Schaik, Erasmus Medical Center, the Netherlands Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:28:40More inScience Technology
Originally posted here:
Session 4: Clinical implementation: a 7 year experience - Video